Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys TNDM Stock
Rep. Gilbert Ray Cisneros Jr. made a recent purchase of Tandem Diabetes shares, adding to his investment portfolio.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Tandem Diabetes Care, Inc. ($TNDM) stock on September 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $TNDM is down 2.5% after 1 week and down 2.0% to date (from the $16.57 close on Sep 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Tandem Diabetes Care, Inc. ($TNDM) | Buy | Sep 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. Find the original: House financial disclosure search
TNDM
Tandem Diabetes Care, Inc.
Key Points
- On September 29, 2026, Rep. Gilbert Ray Cisneros Jr. bought shares of Tandem Diabetes Care, Inc. (TNDM) valued between $1,001 and $15,000.
- The stock recently traded around $16.76, which is significantly below its 52-week high of $29.65 and also below its 50-day moving average of $19.06.
- Cisneros Jr. has been active in the market, having previously sold shares of Workday and W. R. Berkley, and bought shares of The Cooper Companies in June 2026.
Get $TNDM trade alerts by text
We text you when insiders, Congress or big funds trade $TNDM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Tandem Diabetes Care, Inc. alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Tandem Diabetes Care, Inc. (TNDM) on September 29, 2026. The transaction was valued between $1,001 and $15,000 and was reported under the STOCK Act on October 12, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
Inside Gilbert Ray Cisneros Jr.'s Trade
Cisneros Jr. made this purchase as Tandem Diabetes Care continues to operate in the medical devices sector, focusing on technology solutions for diabetes management. The stock is currently trading below its recent moving averages, which might reflect broader market conditions or company-specific factors.
Other Institutional Activity in Tandem Diabetes Care
Several institutional investors have also been active with Tandem Diabetes. Blackrock Inc. holds 11,583,125 shares valued at about $188.1 million, having increased its stake by 892,654 shares. Sessa Capital IM, L.P. owns 5,100,000 shares worth approximately $82.8 million after a gain of 369,456 shares. Vanguard Portfolio Management LLC has 4,299,667 shares valued at around $69.8 million, with an increase of 306,292 shares. Additionally, First Light Asset Management, LLC saw a significant increase of 2,068,837 shares, bringing its total to 3,383,553 shares valued at about $54.9 million.
Tandem Diabetes Care, Inc. Stock Up 1.5%
As of October 16, 2026, Tandem Diabetes Care shares are recently trading at $16.76. This price is about 43.5% below its 52-week high of $29.65 and approximately 12.1% below its 50-day moving average of $19.06. The stock's performance suggests it may be undervalued compared to its historical highs.
Recent Earnings
Tandem Diabetes reported trailing twelve-month revenue of approximately $1.04 billion, showing a year-over-year growth of 5.8%. However, the company also posted a net margin of -6.1% and a return on equity of -48.0%. The next earnings report is expected on November 5, 2026.
Analysts Set New Price Targets
On September 24, 2026, Truist Securities maintained a Buy rating on Tandem Diabetes with a price target of $28.00, down from $31.00. Mizuho and Citigroup both maintained Neutral ratings with targets of $20.00 and $21.00 respectively. RBC Capital also kept an Outperform rating with a target of $26.00, while William Blair initiated coverage with an Outperform rating.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc. designs and develops innovative technology solutions for diabetes management. Its flagship products include the t:slim X2 insulin delivery system and Tandem Mobi insulin pump. The company, based in San Diego, California, aims to improve the lives of people with diabetes through advanced medical devices.
Bottom Line
Rep. Cisneros Jr.'s recent purchase of Tandem Diabetes shares adds to his active trading history, which includes prior sales and purchases in June. Investors will be watching for the upcoming earnings report on November 5, 2026, as well as any further disclosures from Cisneros Jr.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $TNDM (Sep 29, 2026). Find the original filing: House financial disclosure search. Written by software, not financial advice. How we make alerts